Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Szkandera, J; Stotz, M; Absenger, G; Stojakovic, T; Samonigg, H; Kornprat, P; Schaberl-Moser, R; Alzoughbi, W; Lackner, C; Ress, AL; Seggewies, FS; Gerger, A; Hoefler, G; Pichler, M.
Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.
Br J Cancer. 2014; 110(1):183-188
Doi: 10.1038/bjc.2013.701
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Pichler Martin
- Szkandera Joanna
- Co-Autor*innen der Med Uni Graz
- Absenger Gudrun
- Al-Zoughbi Wael
- Gerger Armin
- Höfler Gerald
- Kornprat Peter
- Lackner Karoline
- Lembeck Anna Lena
- Samonigg Hellmut
- Schaberl-Moser Renate
- Seggewies Friederike
- Stojakovic Tatjana
- Stotz Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Recent evidence indicates that the host inflammatory response has an important role in the tumour progression. Elevated C-reactive protein (CRP) levels have been previously associated with poor prognosis in several cancer types including small-scale studies in pancreatic cancer (PC) patients. The purpose of the present study was to validate the prognostic impact of plasma CRP levels at date of diagnosis on cancer-specific survival (CSS) in a large cohort of PC patients. Data from 474 consecutive patients with adenocarcinoma of the pancreas, treated between 2004 and 2012 at a single centre, were evaluated retrospectively. CSS was analysed using the Kaplan-Meier method. To evaluate the prognostic significance of plasma CRP levels, univariate and multivariate Cox analyses were applied. High plasma CRP levels at diagnosis were significantly associated with well-established prognostic factors, including high tumour stage and tumour grade and the administration of chemotherapy (P<0.05). In univariate analysis, we observed that a high plasma CRP level was a consistent factor for poor CSS in PC patients (hazard ratio (HR)=2.21; 95% confidence interval (CI)=1.68-2.92, P<0.001). In multivariate analysis, tumour stage, grade, administration of chemotherapy, a high neutrophil-lymphocyte ratio and the highest quartile of CRP levels (HR=1.60, 95% CI=1.16-2.21; P=0.005) were identified as independent prognostic factors in PC patients. In conclusion, we confirmed a significant association of elevated CRP levels with poor clinical outcome in PC patients. Our results indicate that the plasma CRP level might represent a useful marker for patient stratification in PC management.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- C-Reactive Protein - metabolism
- Carcinoma, Pancreatic Ductal - blood Carcinoma, Pancreatic Ductal - pathology
- Cohort Studies -
- Female -
- Humans -
- Kaplan-Meier Estimate -
- Male -
- Middle Aged -
- Pancreatic Neoplasms - blood Pancreatic Neoplasms - pathology
- Prognosis -
- Proportional Hazards Models -
- Reproducibility of Results -
- Retrospective Studies -
- Find related publications in this database (Keywords)
- C-reactive protein
- prognostic factor
- pancreatic cancer